Auxilium Pharmaceuticals (NASDAQ: AUXL) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it contrast to its competitors? We will compare Auxilium Pharmaceuticals to similar companies based on the strength of its profitability, risk, earnings, dividends, analyst recommendations, valuation and institutional ownership.
This table compares Auxilium Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Auxilium Pharmaceuticals Competitors||-13,099.10%||-105.24%||-26.02%|
This table compares Auxilium Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Auxilium Pharmaceuticals Competitors||$564.12 million||$96.17 million||45.73|
Auxilium Pharmaceuticals’ competitors have higher revenue and earnings than Auxilium Pharmaceuticals. Auxilium Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Auxilium Pharmaceuticals has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Auxilium Pharmaceuticals’ competitors have a beta of 1.08, indicating that their average stock price is 8% more volatile than the S&P 500.
This is a breakdown of recent recommendations and price targets for Auxilium Pharmaceuticals and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Auxilium Pharmaceuticals Competitors||137||801||1760||59||2.63|
As a group, “Biopharmaceuticals” companies have a potential upside of 13.76%. Given Auxilium Pharmaceuticals’ competitors higher probable upside, analysts clearly believe Auxilium Pharmaceuticals has less favorable growth aspects than its competitors.
Institutional and Insider Ownership
43.5% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 15.4% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Auxilium Pharmaceuticals competitors beat Auxilium Pharmaceuticals on 5 of the 8 factors compared.
About Auxilium Pharmaceuticals
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.
Receive News & Ratings for Auxilium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auxilium Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.